Generic Version of Gilenya, pms-Fingolimod, Now Available for RRMS Patients in Canada

Generic Version of Gilenya, pms-Fingolimod, Now Available for RRMS Patients in Canada

Pharmascience recently launched pms-Fingolimod, a generic version of Novartis’ Gilenya (fingolimod), to treat adults with relapsing-remitting multiple sclerosis (RRMS) in Canada. The new generic is now available in that country, and has demonstrated efficacy and safety similar to Gilenya.

Generic medicines are chemically identical to the original branded therapy, but carry a significantly lower cost.

“Pharmascience is proud to offer Canadian patients a therapeutic option that provides the same efficacy and safety as the brand name product. Our generic product is available at an affordable cost to the healthcare system, and is manufactured in Quebec,” Al Moghaddam, vice president and general manager of Pharmascience Canada, said in a press release.

“The launch of pms-Fingolimod reflects our corporate commitment to the Canadian community,” Moghaddam added.

In MS, immune cells called lymphocytes recognize the myelin sheath — the fat-rich substance that wraps around nerve fibers, and works to insulate and increase the velocity of the signals relayed by nerve cells — as foreign, causing inflammation and damaging this protective layer. Without myelin, nerve cells of the central nervous system (brain and spinal cord) start to die, a process known as neurodegeneration.

Fingolimod is an oral disease-modifying therapy that reduces exacerbations in RRMS patients by preventing the destructive action of immune cells against myelin.

At the molecular level, fingolimod is a modulator of the sphingosine 1-phosphate (S1P) receptor present on the surface of lymphocytes, which regulates when immune cells leave lymph nodes. By binding to this receptor, fingolimod prevents lymphocytes from leaving lymph nodes and invading the nervous system. In this way, it reduces both inflammation and neuronal damage.

The new generic, chemically similar to Gilenya, can now be obtained by Canadian patients. pms-Fingolimod capsules of 0.5 milligrams are approved to treat adult RRMS patients, and recommended for those who had an inadequate response or are unable to tolerate one or more MS therapies.

Similar to Gilenya, pms-Fingolimod also offers a patient support program to ensure an easy transition between therapies, called the Ally Patient Support Program. The program offers help with reimbursement, financial assistance, and a point of contact for ongoing support and information about this treatment.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • imaging and MS
  • nerve impulses
  • pms-Fingolimod launch
  • Vumerity approval
Average Rating
5 out of 5 stars. 2 votes.
My Rating:

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

Share This